Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1126
Shown on this page
12
Current sort
Recently updated
Campus scope
Northwestern Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Northwestern Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 961–972 of 1,126 matching trials with a site at Northwestern Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
ASTX660
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting No phase listed Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
Site status not listed — check the official record
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
54
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Recruiting Not applicable Interventional

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

NCT06895070
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Transplant, Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting Not applicable Interventional

RESPONDER-HF Trial

NCT05425459
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic
Interventions
Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Device · Other
Lead sponsor
Corvia Medical
Industry
Eligibility
40 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
33
States / cities
Phoenix, Arizona • La Jolla, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting Not applicable Interventional

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

NCT01570998
Site status not listed — check the official record
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IIA Breast Cancer
Interventions
Intraoperative Radiation Therapy, Laboratory Biomarker Analysis
Radiation · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years and older · Female only
Enrollment
1,259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
25
States / cities
Berkeley, California • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions
Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
Drug · Radiation · Procedure + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Recruiting Phase 4 Interventional

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07225361
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Recruiting No phase listed Observational

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT07207148
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
GLP-1, Ocrelizumab (US)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Recruiting Phase 1 Interventional

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676
Status at this site: Recruiting
View directory record Official record
Conditions
High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions
CBX-250
Drug
Lead sponsor
Crossbow Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Duarte, California • Palo Alto, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
Site status not listed — check the official record
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 4, 2026, 12:14 PM EST
Active, not recruiting No phase listed Observational

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

NCT05639556
Site status not listed — check the official record
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire
Diagnostic Test · Other · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 4, 2026, 12:14 PM EST

About this Northwestern Medicine institution page

What this page lists
ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Northwestern University at any site, browse by condition, or browse by U.S. city.